Disitamab Vedotin (ERBB2/EGFR2/CD340) Antibody, Monoclonal | 10-936

Disitamab Vedotin (ERBB2/EGFR2/CD340) Antibody, Monoclonal | 10-936 | Gentaur UK, US & Europe Distribution

Host: N/A

Reactivity: N/A

Homology: N/A

Immunogen: Humanized / ERBB2/EGFR2/CD340 [Homo sapiens]

Research Area: Drug Analogues

Tested Application: N/A

Application: N/A

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: >95%

Clonality: Monoclonal

Clone: N/A

Isotype: IgG1-kappa

Conjugate: Unconjugated

Physical State: N/A

Buffer: PBS buffer pH7.5

Concentration: N/A

Storage Condition: Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚C for 1-2 weeks. Store at -20 ˚C for 12 months. Store at -80 ˚C for long term storage.

Alternate Name: RC48

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: RC48 (disitamab vedotin) indication is HER2-positive locally advanced or metastatic urothelial carcinoma. RC48 is the first antibody-drug conjugate (ADC) to enter clinical research in China. ADC are made up of monoclonal antibodies, linkers and toxins, which can precisely attack cancer cells like precision-guided missiles. RC48 targets the HER2 protein on the surface of tumors and can accurately identify and bind to cancer cells, penetrate the cell membrane into its interior, and kill cancer cells.